TriSalus Life Sciences, Inc. — Form 8-K Summary
Business context and reporting period
TriSalus Life Sciences, Inc. filed this Form 8-K on April 30, 2024, reporting the execution of a new credit agreement, related warrant issuance, registration rights, and the initial borrowing. The filing does not provide quarterly operating results or financial statements for a reporting period.
Key financial and capital structure matters
- Credit facility: Five-year senior secured credit facility of up to $50 million.
- Initial borrowing: The company borrowed $25 million on April 30, 2024, generating $25 million of gross proceeds.
- Delayed draws: Up to $10 million may become available by June 30, 2025, and up to $15 million by December 31, 2025, subject to specified revenue requirements.
- Maturity: The term loan matures on April 30, 2029.
- Interest: Cash interest accrues at the greater of one-month SOFR and 4.00%, plus 8.50%. The borrower may elect to pay up to 3.50% in kind during the first 15 months after closing.
- Security and guarantees: Obligations are secured by substantially all assets of the company, the borrower, and subsidiary guarantors, with subsidiary guarantees generally required.
- Liquidity covenant: The borrower must maintain unrestricted cash and cash equivalents subject to a first-priority security interest of at least $5 million before March 31, 2025, and at least $10 million thereafter.
- Warrant issuance: The initial lender received a seven-year warrant to purchase 130,805 common shares at $9.5562 per share. Additional warrants may be issued if delayed-draw commitments are funded.
Material changes versus the prior comparable period
The filing reports a material increase in secured indebtedness and liquidity from the initial $25 million borrowing. It does not provide prior-period revenue, profit, cash flow, margin, debt, or liquidity balances for comparison.
Guidance, outlook, risks, contingencies, and unusual items
- Access to delayed-draw commitments depends on meeting revenue requirements tied to the TriNav infusion system.
- If applicable TriNav revenue thresholds are not met, the borrower may be required to repay the outstanding facility in equal monthly installments, together with a repayment premium and other fees.
- Prepayment premiums apply during the first four years after funding; additional commitment, unused, administration, exit, and other lender fees also apply.
- An event of default may increase the interest rate by 4.00% and permit acceleration of the outstanding obligations, repayment premiums, and other fees.
- Customary covenants restrict additional liens and debt, acquisitions and investments, asset transfers, dividends, certain affiliate transactions, amendments to material documents, and other activities.
- Events of default include nonpayment, inaccurate representations, covenant breaches, cross-defaults, insolvency, material judgments, regulatory or permit events, material adverse effects, and change of control.
- The warrant and underlying shares were issued in reliance on private-placement exemptions and were not registered under the Securities Act. The company agreed to file resale registration statements for the warrant shares.
Important facts for investors to verify
- Confirm the facility’s effective interest rate, including the applicable SOFR rate and any payment-in-kind election.
- Monitor compliance with the $5 million and $10 million minimum cash requirements.
- Verify the TriNav revenue thresholds required for the delayed-draw commitments and to avoid mandatory amortization.
- Review the definitive Credit Agreement, warrant, and registration rights documents when filed with the company’s Form 10-Q for the quarter ending June 30, 2024.
- Assess the dilution impact of the initial and any subsequent warrants, including their seven-year terms and adjustment provisions.
- Evaluate prepayment premiums, exit fees, collateral requirements, and default-related acceleration risks.